Join Alamar Biosciences for an expert-led webinar exploring how emerging proteomics technologies—like NULISAseq™ high-sensitivity, multiplexed assays—are enabling more precise, scalable, and non-invasive tools to diagnose, stratify, and monitor traumatic brain injury (TBI), paving the way for improved patient care and therapeutic development.
Dr. David Sharp (Imperial College London) will present insights from his recent publication in Nature Medicine, which identifies distinct proteomic signatures of TBI. Dr. Cheryl Wellington (University of British Columbia) will share her translational research experience applying biomarker discovery approaches across both human and mouse models, highlighting the role of blood-based assays in bridging preclinical and clinical studies.
